
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
The FDA has granted fast-track status to Champix (varenicline), Pfizer's experimental smoking-cessation treatment. The company says the drug helps smokers quit by reducing the severity of cravings and withdrawal symptoms. If the review process begins in January 2006 as expected, approval to begin marketing the product could be granted by July. If approved, the drug is expected to compete with Sanofi-Aventis' Acomplia (rimonabant), which was developed originally for obesity but has been found to be effective in aiding smoking cessation as well.






